You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

List of Excipients in API tobramycin and dexamethasone


✉ Email this page to a colleague

« Back to Dashboard


Excipients in NDA-approved (novel) drugs containing tobramycin and dexamethasone

Glossary
Company Tradename Ingredient NDC Excipient Potential Generic Entry
Alcon Laboratories Inc TOBRADEX tobramycin and dexamethasone 0065-0647 BENZALKONIUM CHLORIDE
Alcon Laboratories Inc TOBRADEX tobramycin and dexamethasone 0065-0647 EDETATE DISODIUM
Alcon Laboratories Inc TOBRADEX tobramycin and dexamethasone 0065-0647 HYDROXYETHYL CELLULOSE
Alcon Laboratories Inc TOBRADEX tobramycin and dexamethasone 0065-0647 SODIUM CHLORIDE
Alcon Laboratories Inc TOBRADEX tobramycin and dexamethasone 0065-0647 SODIUM HYDROXIDE
>Company >Tradename >Ingredient >NDC >Excipient >Potential Generic Entry

Subscribe to access the full database, or Subscribe

Excipients in ANDA-approved (generic) drugs containing tobramycin and dexamethasone

Company Ingredient NDC Excipient
Padagis US LLC tobramycin and dexamethasone 0574-4031 BENZALKONIUM CHLORIDE
Padagis US LLC tobramycin and dexamethasone 0574-4031 EDETATE DISODIUM
Padagis US LLC tobramycin and dexamethasone 0574-4031 HYDROXYETHYL CELLULOSE
Padagis US LLC tobramycin and dexamethasone 0574-4031 SODIUM CHLORIDE
Padagis US LLC tobramycin and dexamethasone 0574-4031 SODIUM HYDROXIDE
>Company >Ingredient >NDC >Excipient

Subscribe to access the full database, or Subscribe

Detailed excipient profiles for tobramycin and dexamethasone

Excipient focus: BENZALKONIUM CHLORIDE

Excipient focus: CHLOROBUTANOL

Excipient focus: EDETATE DISODIUM

Excipient focus: HYDROXYETHYL CELLULOSE

Excipient focus: MINERAL OIL

Excipient focus: PETROLATUM

Excipient focus: SODIUM CHLORIDE

Excipient focus: SODIUM HYDROXIDE

Excipient focus: SODIUM SULFATE

Excipient focus: SULFURIC ACID

Excipient focus: TYLOXAPOL

Excipient focus: WATER

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2024 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
 NCE-1 Patent Challenge Dates 2024 - 2025
 Trigger-based marketing for the life sciences
 Get DrugPatentWatch Business Intelligence Reports at Amazon.com
 DrugChatter - AI-based answers to questions about drugs
 RxJam - Digital Marketing for Life Sciences
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links

Follow DrugPatentWatch:

  DrugPatentWatch Linkedin Group